Sanofi (SNY) has a MoatMap StockRank of 98/100 based on Quality (61/100), Value (75/100), and Momentum (58/100) factor scores. The current signal is STRONG BUY. Sanofi, a major pharmaceutical company, is a high-quality defensive compounder, perfectly aligning with the 'Sticky Rates & Defensive Strength' theme. In a volatile macro environment with persistent inflation and higher rates, its essential products, strong pricing power from patents, and consistent cash flows offer stability and outperformance potential. The 'Durable Compounders at GARP' theme is met by its wide economic moat and reasonable valuation (V:73), positioning it as an attractive investment when consensus is broadly bearish on equities. This creates an asymmetric opportunity for long-term compounding.
Sanofi is a global biopharmaceutical company engaged in the research, development, manufacturing, and marketing of a broad range of healthcare solutions, encompassing prescription drugs, vaccines, and consumer healthcare products. Its significant competitive moat stems from a highly diversified portfolio of patented drugs and vaccines, strong global R&D capabilities, and extensive commercial reach across multiple therapeutic areas. Sanofi is a leading multinational pharmaceutical firm, particularly prominent in vaccine production and innovation in rare diseases and immunology.
| Price | $44.29 |
| Market Cap | $105.9B |
| P/E (TTM) | 18.93 |
| P/E (Forward) | 8.40 |
| Price/Book | 1.25 |
| Return on Equity | 6.6% |
| Return on Invested Capital | 6.9% |
| Debt/Equity | 27.37 |
| Gross Margin | 72.4% |
| Operating Margin | 20.0% |
| Revenue Growth | 6.0% |
| Dividend Yield | 5.5% |
| Free Cash Flow | $16.7B |
Sanofi operates in the Drug Manufacturers - General industry, part of the Healthcare sector (France).